From 2000 to 2017, global funding for coronavirus research amounted to $500 million, or 0.5 percent of total spending on infectious diseases during that period, according to an analysis published in the medical journal The Lancet.
newspaper says,The Wall Street Journal“Although a year and a half has passed since the outbreak of the epidemic, researchers are still struggling to find effective and easy-to-use drugs to treat Covid-19 disease caused by the emerging coronavirus.
The newspaper indicated that the United States agreed and issued a recommendation for the use of ten drugs, two of which were revoked because of their ineffectiveness against Covid-19.
The lack of access to an effective treatment against the coronavirus has exposed flaws in the medical research and healthcare infrastructure, particularly in the fight against a rapidly spreading pandemic.
Federal officials have focused their resources on the rapid development of vaccines, with success.
However, the relative dearth of drug research focused on coronaviruses – despite previous outbreaks – has hampered a rapid response to treatments.
The 2003 outbreaks of severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) in 2012 sparked concern about the need for further research into viruses.
However, interest mostly waned after the previous outbreak of the Corona virus was contained, as most drug researchers focused on finding potentially more profitable treatments for diseases such as cancer, rheumatoid arthritis and hepatitis C, according to the American newspaper.
Current clinical trials are evaluating more than 225 drug treatments for COVID-19, whether they are new drugs or drugs already approved for other disease conditions whose efficacy against the epidemic is being measured, according to data from the Milken Institute, a nonprofit think tank.
In February last year, before the coronavirus was declared a global pandemic, researchers in China and the United States turned to remdesivir as a potential treatment for COVID-19.
University of North Carolina and Vanderbilt researchers, with support from US government grants, have been working with Gilead Sciences since 2014 to verify the drug’s efficacy against the family of coronaviruses.
Experiments showed that it helped remove SARS from the lungs of infected mice, but the problem was that the drug becomes more effective when it is given as soon as possible after infection, and this is what makes the task difficult, given that the drug “Remdisfer” is given to humans by intravenous injection inside the hospital. .
Half of the COVID-19 patients hospitalized in the United States since May 2020 received remdesivir, which was fully approved by the Food and Drug Administration.
However, doctors say patients often recover slowly regardless of whether or not they receive treatment.
And some potential Covid-19 treatments under development showed promising results, as tests are being conducted by some companies, including the American company Pfizer, with a test on antiviral pills that can be taken at home after infection.
Recently, Arab countries, including the UAE and Bahrain, announced promising results for the efficacy of the drug “Sotrovimab” against Covid-19, a drug that received emergency use in the United States by the Food and Drug Administration.